260 related articles for article (PubMed ID: 24708900)
21. Ipilimumab in advanced melanoma: reports of long-lasting responses.
Farolfi A; Ridolfi L; Guidoboni M; Nicoletti SV; Piciucchi S; Valmorri L; Costantini M; Scarpi E; Amadori D; Ridolfi R
Melanoma Res; 2012 Jun; 22(3):263-70. PubMed ID: 22516968
[TBL] [Abstract][Full Text] [Related]
22. Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma.
Simeone E; Gentilcore G; Giannarelli D; Grimaldi AM; Caracò C; Curvietto M; Esposito A; Paone M; Palla M; Cavalcanti E; Sandomenico F; Petrillo A; Botti G; Fulciniti F; Palmieri G; Queirolo P; Marchetti P; Ferraresi V; Rinaldi G; Pistillo MP; Ciliberto G; Mozzillo N; Ascierto PA
Cancer Immunol Immunother; 2014 Jul; 63(7):675-83. PubMed ID: 24695951
[TBL] [Abstract][Full Text] [Related]
23. Phase II Study of Autologous Monocyte-Derived mRNA Electroporated Dendritic Cells (TriMixDC-MEL) Plus Ipilimumab in Patients With Pretreated Advanced Melanoma.
Wilgenhof S; Corthals J; Heirman C; van Baren N; Lucas S; Kvistborg P; Thielemans K; Neyns B
J Clin Oncol; 2016 Apr; 34(12):1330-8. PubMed ID: 26926680
[TBL] [Abstract][Full Text] [Related]
24. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.
Postow MA; Chesney J; Pavlick AC; Robert C; Grossmann K; McDermott D; Linette GP; Meyer N; Giguere JK; Agarwala SS; Shaheen M; Ernstoff MS; Minor D; Salama AK; Taylor M; Ott PA; Rollin LM; Horak C; Gagnier P; Wolchok JD; Hodi FS
N Engl J Med; 2015 May; 372(21):2006-17. PubMed ID: 25891304
[TBL] [Abstract][Full Text] [Related]
25. Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain.
Tawbi HA; Forsyth PA; Algazi A; Hamid O; Hodi FS; Moschos SJ; Khushalani NI; Lewis K; Lao CD; Postow MA; Atkins MB; Ernstoff MS; Reardon DA; Puzanov I; Kudchadkar RR; Thomas RP; Tarhini A; Pavlick AC; Jiang J; Avila A; Demelo S; Margolin K
N Engl J Med; 2018 Aug; 379(8):722-730. PubMed ID: 30134131
[TBL] [Abstract][Full Text] [Related]
26. Patterns of response in patients with pretreated metastatic melanoma who received ipilimumab 3 mg/kg in a European expanded access program: five illustrative case reports.
Wilgenhof S; Du Four S; Everaert H; Neyns B
Cancer Invest; 2012 Dec; 30(10):712-20. PubMed ID: 23043499
[TBL] [Abstract][Full Text] [Related]
27. A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma.
Hersh EM; O'Day SJ; Powderly J; Khan KD; Pavlick AC; Cranmer LD; Samlowski WE; Nichol GM; Yellin MJ; Weber JS
Invest New Drugs; 2011 Jun; 29(3):489-98. PubMed ID: 20082117
[TBL] [Abstract][Full Text] [Related]
28. Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial.
Carlino MS; Long GV; Schadendorf D; Robert C; Ribas A; Richtig E; Nyakas M; Caglevic C; Tarhini A; Blank C; Hoeller C; Bar-Sela G; Barrow C; Wolter P; Zhou H; Emancipator K; Jensen EH; Ebbinghaus S; Ibrahim N; Daud A
Eur J Cancer; 2018 Sep; 101():236-243. PubMed ID: 30096704
[TBL] [Abstract][Full Text] [Related]
29. Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma.
Schadendorf D; Hodi FS; Robert C; Weber JS; Margolin K; Hamid O; Patt D; Chen TT; Berman DM; Wolchok JD
J Clin Oncol; 2015 Jun; 33(17):1889-94. PubMed ID: 25667295
[TBL] [Abstract][Full Text] [Related]
30. Long-term Survival with Ipilimumab: Experience from a National Expanded Access Program for Patients with Melanoma.
Krajsová I; Arenberger P; Lakomý R; Kubala E; Březinová I; Poprach A; Šťastný M; Mužík J; Melichar B
Anticancer Res; 2015 Nov; 35(11):6303-10. PubMed ID: 26504067
[TBL] [Abstract][Full Text] [Related]
31. Adverse events need for hospitalization and systemic immunosuppression in very elderly patients (over 80 years) treated with ipilimumab for metastatic melanoma.
Leroy V; Gerard E; Dutriaux C; Prey S; Gey A; Mertens C; Beylot-Barry M; Pham-Ledard A
Cancer Immunol Immunother; 2019 Apr; 68(4):545-551. PubMed ID: 30661086
[TBL] [Abstract][Full Text] [Related]
32. Ipilimumab in the real world: the UK expanded access programme experience in previously treated advanced melanoma patients.
Ahmad SS; Qian W; Ellis S; Mason E; Khattak MA; Gupta A; Shaw H; Quinton A; Kovarikova J; Thillai K; Rao A; Board R; Nobes J; Dalgleish A; Grumett S; Maraveyas A; Danson S; Talbot T; Harries M; Marples M; Plummer R; Kumar S; Nathan P; Middleton MR; Larkin J; Lorigan P; Wheater M; Ottensmeier CH; Corrie PG
Melanoma Res; 2015 Oct; 25(5):432-42. PubMed ID: 26225580
[TBL] [Abstract][Full Text] [Related]
33. Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival.
Ku GY; Yuan J; Page DB; Schroeder SE; Panageas KS; Carvajal RD; Chapman PB; Schwartz GK; Allison JP; Wolchok JD
Cancer; 2010 Apr; 116(7):1767-75. PubMed ID: 20143434
[TBL] [Abstract][Full Text] [Related]
34. Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study.
Najjar YG; Navrazhina K; Ding F; Bhatia R; Tsai K; Abbate K; Durden B; Eroglu Z; Bhatia S; Park S; Chowdhary A; Chandra S; Kennedy J; Puzanov I; Ernstoff M; Vachhani P; Drabick J; Singh A; Xu T; Yang J; Carvajal R; Manson D; Kirkwood JM; Cohen J; Sullivan R; Johnson D; Funchain P; Shoushtari A
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581057
[TBL] [Abstract][Full Text] [Related]
35. Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme.
Di Giacomo AM; Calabrò L; Danielli R; Fonsatti E; Bertocci E; Pesce I; Fazio C; Cutaia O; Giannarelli D; Miracco C; Biagioli M; Altomonte M; Maio M
Cancer Immunol Immunother; 2013 Jun; 62(6):1021-8. PubMed ID: 23591982
[TBL] [Abstract][Full Text] [Related]
36. Prognostic score for patients with advanced melanoma treated with ipilimumab.
Diem S; Kasenda B; Martin-Liberal J; Lee A; Chauhan D; Gore M; Larkin J
Eur J Cancer; 2015 Dec; 51(18):2785-91. PubMed ID: 26597444
[TBL] [Abstract][Full Text] [Related]
37. A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma.
Hamid O; Schmidt H; Nissan A; Ridolfi L; Aamdal S; Hansson J; Guida M; Hyams DM; Gómez H; Bastholt L; Chasalow SD; Berman D
J Transl Med; 2011 Nov; 9():204. PubMed ID: 22123319
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study.
O'Day SJ; Maio M; Chiarion-Sileni V; Gajewski TF; Pehamberger H; Bondarenko IN; Queirolo P; Lundgren L; Mikhailov S; Roman L; Verschraegen C; Humphrey R; Ibrahim R; de Pril V; Hoos A; Wolchok JD
Ann Oncol; 2010 Aug; 21(8):1712-1717. PubMed ID: 20147741
[TBL] [Abstract][Full Text] [Related]
39. Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders.
Johnson DB; Sullivan RJ; Ott PA; Carlino MS; Khushalani NI; Ye F; Guminski A; Puzanov I; Lawrence DP; Buchbinder EI; Mudigonda T; Spencer K; Bender C; Lee J; Kaufman HL; Menzies AM; Hassel JC; Mehnert JM; Sosman JA; Long GV; Clark JI
JAMA Oncol; 2016 Feb; 2(2):234-40. PubMed ID: 26633184
[TBL] [Abstract][Full Text] [Related]
40. Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial.
Ascierto PA; Del Vecchio M; Robert C; Mackiewicz A; Chiarion-Sileni V; Arance A; Lebbé C; Bastholt L; Hamid O; Rutkowski P; McNeil C; Garbe C; Loquai C; Dreno B; Thomas L; Grob JJ; Liszkay G; Nyakas M; Gutzmer R; Pikiel J; Grange F; Hoeller C; Ferraresi V; Smylie M; Schadendorf D; Mortier L; Svane IM; Hennicken D; Qureshi A; Maio M
Lancet Oncol; 2017 May; 18(5):611-622. PubMed ID: 28359784
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]